SpringWorks Therapeutics’ Gomekli is now FDA approved for treating tumors caused by the rare genetic disorder neurofibromatosis type 1. The approval comes as SpringWorks has emerged as a potential acquisition target.
SpringWorks Therapeutics drug Ogsiveo is now FDA-approved for treating desmoid tumors, a type of tumor affecting connective tissue. The regulatory decision makes the pill the first therapy approved specifically for treating this rare disorder.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
“In a lot of ways, it starts with patient groups, who help us look at the landscape and understand where the science is that may not be organically happening in the industry right now,” said Lara Sullivan, founder and president of Pfizer spin-off SpringWorks.